CG
REGN icon

Cutler Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Cutler Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-700
Closed -$482K – 5064
2022
Q3 		$482K Buy
700
+528
+307% +$332K 0.03% 540
2022
Q2 		$101K Sell
172
-1,800
-91% -$1.17M 0.01% 1442
2022
Q1 		$1.38M Buy
+1,972
New +$1.25M 0.07% 302
2020
Q1 		– Sell
-116
Closed -$43K – 4527
2019
Q4 		$43K Buy
+116
New +$39K ﹤0.01% 1729
2018
Q1 		– Sell
-5,484
Closed -$1.91M – 5070
2017
Q4 		$2.06M Buy
5,484
+877
+19% +$355K 0.08% 168
2017
Q3 		$2.06M Buy
4,607
+1,209
+36% +$575K 0.08% 191
2017
Q2 		$1.67M Sell
3,398
-405
-11% -$177K 0.06% 257
2017
Q1 		$1.47M Buy
3,803
+703
+23% +$261K 0.06% 264
2016
Q4 		$1.14M Buy
3,100
+470
+18% +$179K 0.04% 371
2016
Q3 		$1.06M Hold
2,630
– – 0.05% 308
2016
Q2 		$918K Sell
2,630
-650
-20% -$250K 0.05% 314
2016
Q1 		$1.18M Buy
3,280
+2,030
+162% +$836K 0.08% 224
2015
Q4 		$678K Buy
+1,250
New +$677K 0.04% 489

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cutler Group's REGN Position: Q4 2022 in Review

Cutler Group sold out of Regeneron Pharmaceuticals (REGN) in Q4 2022, closing a stake of 700 shares — an estimated $482K sold.

Cutler Group first reported a position in REGN in Q4 2015 and held it in 13 quarters. The position peaked at $2.06M in Q4 2017. 1,158 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

  • Cutler Group reported no remaining Regeneron Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 700 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $482K.
  • Cutler Group first reported a position in Regeneron Pharmaceuticals in Q4 2015 and held it in 13 quarters.
  • Cutler Group's Regeneron Pharmaceuticals position peaked at $2.06M in Q4 2017.
  • 1,158 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.